Mirvetuximab Soravtansine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Mirvetuximab Soravtansine
DrugBank Accession Number
DB12489
Background

Mirvetuximab Soravtansine has been used in trials studying the treatment of Ovarian cancer, Endometrial Cancer, Fallopian tube cancer, Epithelial Ovarian Cancer, and Primary Peritoneal Cancer, among others.

Type
Biotech
Groups
Investigational
Synonyms
  • IMGN853
  • Mirvetuximab Soravtansine

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Mirvetuximab Soravtansine.
AbemaciclibThe metabolism of Abemaciclib can be decreased when combined with Mirvetuximab Soravtansine.
AcalabrutinibThe metabolism of Acalabrutinib can be decreased when combined with Mirvetuximab Soravtansine.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Mirvetuximab Soravtansine.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Mirvetuximab Soravtansine.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Mirvetuximab Soravtansine.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Mirvetuximab Soravtansine.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Mirvetuximab Soravtansine.
AlectinibThe metabolism of Alectinib can be decreased when combined with Mirvetuximab Soravtansine.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mirvetuximab Soravtansine.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
98DE7VN88D
CAS number
1453084-37-1

References

General References
Not Available
PubChem Compound
131704323
PubChem Substance
347828725
ChemSpider
64873336

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentFallopian Tubes Cancer / Malignant Peritoneal Neoplasm / Ovarian Cancer (Epithelial)1
3CompletedTreatmentFallopian Tubes Cancer / Ovarian Cancer / Ovarian Cancer (Epithelial) / Primary Peritoneal Carcinoma1
3RecruitingTreatmentFallopian Tubes Cancer / Malignant Peritoneal Neoplasm / Ovarian Cancer (Epithelial)1
2CompletedTreatmentAnatomic Stage II Breast Cancer AJCC v8 / Anatomic Stage IIA Breast Cancer AJCC v8 / Anatomic Stage IIB Breast Cancer AJCC v8 / Anatomic Stage III Breast Cancer AJCC v8 / Anatomic Stage IIIA Breast Cancer AJCC v8 / Anatomic Stage IIIB Breast Cancer AJCC v8 / Anatomic Stage IIIC Breast Cancer AJCC v8 / Anatomic Stage IV Breast Cancer AJCC v8 / Estrogen Receptor Negative / Folate Receptor Alpha Positive / HER2/Neu Negative / Progesterone Receptor Negative / Prognostic Stage 2 Breast Cancer AJCC v8 / Prognostic Stage IIA Breast Cancer AJCC v8 / Prognostic Stage IIB Breast Cancer AJCC v8 / Prognostic Stage III Breast Cancer AJCC v8 / Prognostic Stage IIIA Breast Cancer AJCC v8 / Prognostic Stage IIIB Breast Cancer AJCC v8 / Prognostic Stage IIIC Breast Cancer AJCC v8 / Prognostic Stage IV Breast Cancer AJCC v8 / Triple Negative Breast Carcinoma1
2Not Yet RecruitingTreatmentRecurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma1
2RecruitingTreatmentEndometrial Cancer2
2RecruitingTreatmentFallopian Tubes / Ovarian Cancer / Primary Peritoneal Cancer1
2WithdrawnTreatmentEndometrial Adenocarcinomas / Endometrial Cancer / Endometrial Clear Cell Adenocarcinoma / Endometrial Serous Adenocarcinoma1
1Active Not RecruitingTreatmentBRCA 1 Gene Mutation / Brca2 Gene Mutation / Folate Receptor Alpha Positive / Platinum-resistant Ovarian Cancer (PROC) / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Recurrent Uterine Carcinosarcoma / Recurrent Uterine Corpus Carcinoma / Recurrent Uterine Serous Carcinoma1
1CompletedTreatmentTumors1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. doi: 10.2165/00003088-200039030-00003. [Article]

Drug created on October 20, 2016 22:35 / Updated on February 21, 2021 18:53